Back to Search Start Over

Cognitive Profile and Mental Health in Adult Phenylketonuria

Authors :
Annet M. Bosch
Ans T. van der Ploeg
Martijn C. G. J. Brouwers
Mirian C. H. Janssen
Rianne Jahja
Leo M. J. de Sonneville
C. E. M. Hollak
Stephan C. J. Huijbregts
Janneke G. Langendonk
Jaap van der Meere
Floris C. Hofstede
Amanda M. Legemaat
Maaike de Vries
M. Estela Rubio-Gozalbo
Francjan J. van Spronsen
Amsterdam Gastroenterology Endocrinology Metabolism
Paediatric Metabolic Diseases
Endocrinology
Pediatrics
Internal Medicine
MUMC+: MA Medische Staf Kindergeneeskunde (9)
RS: GROW - R4 - Reproductive and Perinatal Medicine
Kindergeneeskunde
MUMC+: MA Endocrinologie (9)
RS: CARIM - R3.01 - Vascular complications of diabetes and the metabolic syndrome
Interne Geneeskunde
Clinical Neuropsychology
Center for Liver, Digestive and Metabolic Diseases (CLDM)
Source :
Neuropsychology, 31(4), 437-447. American Psychological Association Inc., Neuropsychology, 31, 4, pp. 437-447, Neuropsychology, 31(4), 437-447. American Psychological Association, Neuropsychology, 31(4), 437. American Psychological Association Inc., Neuropsychology, 31(4), 437-447. AMER PSYCHOLOGICAL ASSOC, Neuropsychology, 31, 437-447
Publication Year :
2017

Abstract

Item does not contain fulltext OBJECTIVE: Despite early dietary treatment phenylketonuria patients have lower IQ and poorer executive functions compared to healthy controls. Cognitive problems in phenylketonuria have often been associated with phenylalanine levels. The present study examined the cognitive profile and mental health in adult phenylketonuria, in relation to phenylalanine levels and tetrahydrobiopterin treatment. METHOD: Fifty-seven early treated adult patients with phenylketonuria and 57 healthy matched controls (18-40 years) performed IQ subtests and executive function tests from the Amsterdam Neuropsychological Tasks. They also completed the Adult Self-Report on mental health problems. Analyses of variance were performed to examine group differences. RESULTS: Patients with phenylketonuria had normal IQs although lower than controls. They performed poorer on working memory, inhibitory control, and sustained attention tasks. Patients reported Depressive and Avoidant Personality problems more frequently. Specifically, patients with childhood and lifetime phenylalanine >/=360 mumol/L had poorer cognitive and mental health outcomes than controls. In a subset of patients, comparisons between patients on and off tetrahydrobiopterin showed that nontetrahydrobiopterin users (matched for childhood, pretreatment phenylalanine) were slower (on number of tasks) and reported more mental health problems. CONCLUSIONS: Adult patients had lower IQ and poorer executive functions than controls, resembling problems observed in younger patients with phenylketonuria, as well as more internalizing problems. Group differences and phenylalanine-outcome associations were smaller than those observed in younger populations. A subset of nontetrahydrobiopterin users, matched for childhood phenylalanine level, had a poorer outcome on some tests than tetrahydrobiopterin users, which might indicate an impact of tetrahydrobiopterin treatment beyond lowering phenylalanine. However, clinical relevance needs further investigation. (PsycINFO Database Record

Details

Language :
English
ISSN :
08944105
Volume :
31
Issue :
4
Database :
OpenAIRE
Journal :
Neuropsychology
Accession number :
edsair.doi.dedup.....9d533cfac5fa9bbc67eae709e647f48b
Full Text :
https://doi.org/10.1037/neu0000358